• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Algernon Pharmaceuticals Inc (OP: AGNPF )

    0.0628 +0.0025 (+4.15%)
    Streaming Delayed Price Updated: 12:42 PM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Algernon Pharmaceuticals Inc

    Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
    Via Benzinga
    DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
    Via Benzinga
    Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
    First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
    Via Benzinga
    DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
    Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) (CSE:AGN) (FRANKFURT:AGW0), has completed a feasibility study and has finalized its clinical trial design... 
    Via Benzinga
    Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
    Via Benzinga
    DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
    Algernon Pharmaceuticals’ (OTCQB: AGNPF) wholly-owned Algernon NeuroScience (AGN Neuro) successfully completed dosing the third and final cohort of its Phase 1 clinical study assessing an intravenous... 
    Via Benzinga
    How To Finance A Psychedelics Business? Learn From These Four Companies
    Clearmind Medicine Announces Pricing of $3.5 Million Public Offering 
    Via Benzinga
    Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
    Canadian biopharma company Algernon Pharmaceuticals Inc. 
    Via Benzinga
    Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
    Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
    Via Benzinga
    Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
    In this new podcast, TDR Founder Shadd Dales interviewed Algernon Pharmaceuticals (OTC: AGNPF) CEO, Christopher Moreau. 
    Via Benzinga
    Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
    Canadian clinical-stage psychedelics developer Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) will start trading its Class A common shares following a 4-to-1 stock split towards increasing liquidity.  
    Via Benzinga
    Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
    Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and... 
    Via Benzinga
    Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
    Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and... 
    Via Benzinga
    Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
    Biopharma company Algernon Pharmaceuticals (OTCQB: AGNPF) has launched a new clinical research program via a subsidiary. 
    Via Benzinga
    Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
    Algernon Pharmaceuticals (OTCQB: AGNPF)’s subsidiary Algernon NeuroScience has completed the first cohort in its Phase 1 clinical study of 
    Via Benzinga
    A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
    Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed 
    Via Benzinga
    Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
    The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. 
    Via Benzinga
    EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
    Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. 
    Via Benzinga
    Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
    Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy 
    Via Benzinga
    Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
    Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. 
    Via Benzinga
    Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
    Canadian-based psychedelics biopharma company Algernon Pharmaceuticals Inc. 
    Via Benzinga
    A Foundational Study On Stroke Is Ready. Here Is Why It's Important
    Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for huma 
    Via Benzinga
    Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
    Algernon Pharmaceuticals Inc. (OTCQB: AGNPF) has set up a clinical research program for the treatment of strokes, focused on its proprietary DMT analogue, AP-188. The company is also planning to begin... 
    Via Benzinga
    Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
    Biotech clinical-stage company Algernon Pharmaceuticals Inc. 
    Via Benzinga
    Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
    The Week In Psychedelics 
    Via Benzinga
    Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
    Last Week In Psychedelics: 
    Via Benzinga
    How To Invest In "Magic Mushrooms" (Psychedelics)
    A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
    Via Talk Markets
    There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
    Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
    Via Benzinga
    Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
    This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... 
    Via Benzinga
    Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
    Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... 
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.